Literature DB >> 2703008

ChlVPP chemotherapy in advanced Hodgkin's disease.

J J McKendrick1, G M Mead, J Sweetenham, D H Jones, C J Williams, R Ryall, J M Whitehouse.   

Abstract

Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703008     DOI: 10.1016/0277-5379(89)90270-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.

Authors:  A M Oza; T S Ganesan; M Dorreen; P W Johnson; J Waxman; W Gregory; J Lim; J Wright; L Dadiotis; V Barbounis
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

2.  Has the MOPP era ended?

Authors:  G P Canellos
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

3.  ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

Authors:  P Selby; P Patel; S Milan; M Meldrum; J Mansi; E Mbidde; M Brada; T Perren; G Forgeson; M Gore
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.